Beyond Air, Inc. filings document the regulatory record for a commercial-stage nitric oxide medical device and biopharmaceutical company. Proxy materials cover stockholder votes on charter amendments, reverse stock-split authority, director elections, auditor ratification, and equity incentive plan share reserves.
Form 8-K disclosures record material events such as executive officer transitions, separation agreements, Nasdaq continued-listing compliance notices, annual meeting results, material agreements, capital-structure matters, operating and financial results, and clinical or regulatory disclosures tied to the company's nitric oxide programs.
Beyond Air, Inc. (XAIR) reported revenue of $2.324 million for the quarter ended September 30, 2026, up approximately 28% year over year and 31% from the prior quarter. Net loss attributable to Beyond Air was $7.818 million, versus $7.940 million; loss per share was $3.76 versus $24.98. Research and development expense was $1.581 million, compared with $2.450 million, while selling, general and administrative expense was $4.591 million versus $4.913 million. Other expense was $2.200 million, compared with $0.597 million, reflecting higher debt-related interest expense and a charge for scrapped materials.
As of September 30, cash, cash equivalents, restricted cash and marketable securities totaled $18.5 million. Beyond Air reaffirmed revenue guidance of $8 million for 2026, excluding second-generation LungFit PH, and $16 million to $18 million for 2027, including anticipated revenue from that system pending FDA approval. Its PMA supplement remains under FDA review; audit-readiness completion is expected in mid-December, subject to FDA inspections and final approval thereafter. A definitive agreement provides for UNIVO to acquire Beyond Air’s controlling interest in NeuroNOS Israel Ltd. The company cites substantial doubt about its ability to continue as a going concern.
Beyond Air, Inc. reported revenue of $2.324 million for the quarter ended September 30, 2026, compared with $1.818 million a year earlier, and gross profit of $197,000 versus a $298,000 gross loss. Net loss was $8.175 million, versus $8.258 million.
For the six months ended September 30, 2026, revenue was $4.092 million versus $3.578 million, while net cash used in operating activities was $10.514 million versus $8.979 million. Cash, cash equivalents and marketable securities were $13.7 million as of September 30, 2026. Management expects net losses and significant cash outflows for at least the next year and said additional funding is required within one year of issuance. It said these factors raise substantial doubt about its ability to meet obligations with cash on hand; it also said there can be no assurance additional financing will be available when needed or on acceptable terms.
A July private placement closed with $9.1 million in net proceeds. In August, Beyond Air agreed to sell its entire controlling stake in NeuroNOS Israel to UNIVO in exchange for UNIVO ordinary shares and five-year warrants, with eligibility for up to $32.5 million in future cash milestone payments under a separate intellectual property transfer agreement. The transaction is expected to close in December 2026, subject to customary closing conditions, including regulatory and stock exchange clearances.
Beyond Air, Inc. (XAIR) will hold its annual meeting in person on December 10, 2026, at 4:30 p.m. Eastern Time. Stockholders of record on October 12, 2026 may vote; 1,665,482 common shares were outstanding on that date. Proposals include electing five directors, ratifying WithumSmith+Brown, PC for the transition period, an advisory vote on named executive officer compensation, and possible adjournment or postponement.
The company changed its fiscal year-end from March 31 to December 31. April 1 through December 31, 2026 is the transition period, and the next fiscal year begins January 1, 2027. CEO Robert S. Goodman’s September 23, 2026 employment agreement provides for annual base salary of at least $650,000 and a target bonus of 60% of base salary, with a possible award of 0% to 150% of target based on performance objectives. CFO Daniel Moorhead’s annual salary was increased to $463,000 on September 23, 2026, and he was granted an option to purchase 3,500 shares.
Beyond Air, Inc. (XAIR) is the issuer for Yi-Chien Lin’s amended beneficial-ownership report, which lists 148,000 common shares, or 8.9%, with sole voting and dispositive power. Lin reported that the percentage declined from 14.8% to 8.9% solely because Beyond Air’s common shares outstanding increased to 1,665,482 as of October 12, 2026. Lin stated he is no longer subject to Section 16 as a 10% beneficial owner.
Beyond Air, Inc. asks stockholders to elect five directors and vote on ratifying WithumSmith+Brown, PC as independent registered public accounting firm for the April 1, 2026 to December 31, 2026 transition period, an advisory nonbinding executive-compensation proposal, and adjournment or postponement if needed. The annual meeting is set for December 10, 2026. There were 1,665,482 common shares outstanding as of October 12, 2026, the record date. The board recommends a vote “FOR” each proposal. The company changed its fiscal year-end from March 31 to December 31.
CEO Robert S. Goodman’s agreement sets annual base salary at not less than $650,000 and a target annual bonus of 60% of base salary. CFO Daniel Moorhead’s annual salary increased to $463,000 effective September 23, 2026, and he received an option to purchase 3,500 shares. Former CEO Steven A. Lisi’s separation agreement provides $650,000 in salary continuation over 12 months, COBRA premiums for 12 months, and full vesting of his unvested options and restricted stock unit awards on March 27, 2026.
Beyond Air, Inc. (XAIR) ten percent owner Lin Yi-Chien purchased 2,607 shares of common stock on October 13, 2026, at $2.21 per share. The transaction was reported as a direct purchase; reported direct holdings after it were 148,000 shares. No Rule 10b5-1 plan is reported.
Beyond Air, Inc. (XAIR) announced preliminary, unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026, its highest quarterly revenue reported. The company said revenue increased approximately 30% from the quarter ended June 30, 2026 and 27% from the same quarter last year, reflecting continued adoption of first-generation LungFit PH.
Beyond Air reaffirmed revenue guidance of $8 million for calendar 2026, excluding second-generation LungFit PH revenue, and $16 million to $18 million for calendar 2027, which includes anticipated revenue from the second-generation system, pending FDA approval. That system remains under FDA review. The quarterly estimate is based on management’s preliminary estimates and information available as of October 8, 2026; it is subject to completion of financial closing procedures and review of interim financial statements. The independent registered public accounting firm has not audited, reviewed or performed procedures on the preliminary figure, and actual revenue may differ materially. Beyond Air expects to report complete quarterly results in November 2026.
Beyond Air, Inc. (XAIR) ten percent owner Lin Yi-Chien reported three direct purchases totaling 20,393 shares of common stock: 15,393 on October 1, 2026, at a $2.80 weighted-average price; 2,000 on September 30 at $2.71; and 3,000 on September 29 at $2.69. Each reported price is a weighted average; the underlying purchases were at prices ranging from $2.67 to $2.85, inclusive. No Rule 10b5-1 plan is reported.
Beyond Air, Inc. (XAIR) is identified in a Form 3 showing ten percent owner Lin Yi-Chien’s direct holding of 125,000 shares of Common Stock as of September 28, 2026.
Beyond Air, Inc. (XAIR) common stock is the subject of Yi-Chien Lin’s reported beneficial ownership of 145,393 shares, equal to 14.8% of the class. Lin reported sole voting power and sole dispositive power over 145,393 shares.